Paper Details

  1. Home
  2. Paper Details

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.

Author: DecourtJ P, DenissenJ, ErdmanK, FourtillanJ B, GiraultJ, GrannemanG R, HsuA, LeonardJ M, LockeC, LyonsN, MollaA, NiuP, SmithJ, ValdesJ, WittG

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Ritonavir, an HIV treatment, showed moderately dose-dependent pharmacokinetics with concentration-dependent autoinduction. Triglyceride levels increased with higher ritonavir doses. This data provides information about its absorption, elimination, and potential side effects.
Paper Details　
Original Abstract of the Article :
The multiple-dose pharmacokinetics of ritonavir were investigated in four groups of human immunodeficiency virus-positive male subjects (with 16 subjects per group) under nonfasting conditions; a 3:1 ritonavir:placebo ratio was used. Ritonavir was given at 200 (group I), 300 (group II), 400 (group I...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1128/AAC.41.5.898

データ提供：米国国立医学図書館（NLM）

Understanding the Pharmacokinetics of Ritonavir in HIV-Infected Individuals

This research takes us deep into the desert of HIV treatment, exploring the pharmacokinetics of ritonavir in HIV-infected individuals. Think of pharmacokinetics as the journey of a drug through the body, a complex dance of absorption, distribution, metabolism, and elimination. The study aimed to map out this journey for ritonavir, a powerful antiviral drug, seeking to understand how its effectiveness changes with different doses and over time. They discovered that ritonavir's pharmacokinetics are moderately dose-dependent, meaning that higher doses lead to lower clearance rates, potentially increasing its effectiveness. This knowledge is crucial for optimizing treatment regimens.

A Closer Look at Ritonavir's Journey

This research provides valuable insights into ritonavir's pharmacokinetic profile in HIV-infected individuals. The study showed that ritonavir's effectiveness can vary depending on the dose and the duration of treatment. This understanding is essential for clinicians to tailor treatment plans to individual patients and optimize therapy outcomes.

Navigating HIV Treatment: A Collaborative Effort

The insights gained from this study underscore the importance of close collaboration between healthcare providers and patients in managing HIV. Regular monitoring and adjustments to treatment regimens are essential to ensure optimal effectiveness and minimize side effects.

Dr.Camel's Conclusion

This research illuminates the complexities of ritonavir's pharmacokinetics in HIV-infected individuals, offering valuable insights for optimizing treatment regimens. This study is a reminder that understanding the intricate pathways of drug absorption and elimination is crucial for effective HIV management.
Date :
  1. Date Completed 1997-08-21
  2. Date Revised 2020-07-24
Further Info :

Pubmed ID

9145841

DOI: Digital Object Identifier

10.1128/AAC.41.5.898

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.